A listing of Cardiomyopathy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This study is being done to help potentially improve or stabilize heart failure related to transthyretin amyloidosis. The plan is to administer this investigational drug (ION-682884) 45 mg subcutaneously every 4 weeks.
The goal of this study is to learn about prediction of sudden death in children and adolescents with hypertrophic cardiomyopathy. We are hoping to find out if the use of genetic results and heart imaging will improve the ability to assess risk of sudden death in children.
he purpose of this prospective study is to assess the accuracy of four previously-studied genetic variations to predict the development of cardiomyopathy (i.e., a disease of the heart muscle that reduces the ability of your heart to pump blood to your body) in adult subjects during or following treatment with …
Duchenne muscular dystrophy (DMD) is a devastating X-linked disease which leads to loss of ambulation between ages 7 and 13, respiratory failure and cardiomyopathy (CM) at any age, and inevitably premature death of affected young men in their late twenties. DMD is the most common fatal genetic disorder diagnosed in …
To evaluate the safety of mavacamten in patients with symptomatic obstructive hypertrophiccardiomyopathy (obstructive HCM) in the real-world setting. The registry evaluates patient characteristics, realworld treatment patterns and short- and long-term outcomes in a population of patients with symptomaticobstructive HCM who are receiving mavacamten, receiving other treatment for obstructive HCM, or …
To evaluate the efficacy of eplontersen compared to placebo in participants with ATTR-CM receiving available standard of care (SoC). For more information, please visit https://www.cardio-ttransform.com.
The primary purpose of this study is to examine the safety and feasibility of delivering allogeneic human mesenchymal stem cells (allo-MSCs) by transendocardial injection to cancer survivors with left ventricular (LV) dysfunction secondary to anthracycline-induced cardiomyopathy (AIC).